Cargando…
US Food and Drug Administration regulatory updates in neuro-oncology
OBJECTIVE: Contemporary management of patients with neuro-oncologic disease requires an understanding of approvals by the US Food and Drug Administration (FDA) related to nervous system tumors. To summarize FDA updates applicable to neuro-oncology practitioners, we sought to review oncology product...
Autores principales: | Mehta, Gautam U., Barone, Amy K., Bradford, Diana, Larkins, Erin, Kim, Janice, Pai-Scherf, Lee, Jaigirdar, Adnan, Shah, Mirat, Wedam, Suparna, Amiri-Kordestani, Laleh, Theoret, Marc R., Pazdur, Richard, Beaver, Julia A., Singh, Harpreet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218275/ https://www.ncbi.nlm.nih.gov/pubmed/34156585 http://dx.doi.org/10.1007/s11060-021-03789-5 |
Ejemplares similares
-
Oncology approvals in 2020: a year of firsts in the midst of a pandemic
por: Amiri-Kordestani, Laleh, et al.
Publicado: (2021) -
Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
por: Chang, Elaine, et al.
Publicado: (2021) -
Inpatient and outpatient case prioritization for patients with neuro-oncologic disease amid the COVID-19 pandemic: general guidance for neuro-oncology practitioners from the AANS/CNS Tumor Section and Society for Neuro-Oncology
por: Ramakrishna, Rohan, et al.
Publicado: (2020) -
Patient‐Friendly Language to Facilitate Treatment Choice for Patients with Cancer
por: Kim, Janice, et al.
Publicado: (2019) -
Ethical considerations of neuro-oncology trial design in the era of precision medicine
por: Gupta, Saksham, et al.
Publicado: (2017)